Search hospitals > Ohio > Cincinnati
Good Samaritan Hospital - Cincinnati
Claim this profileCincinnati, Ohio 45220
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Lung Cancer
Conducts research for Recurrence
326 reported clinical trials
7 medical researchers
Summary
Good Samaritan Hospital - Cincinnati is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Lung Cancer, Recurrence and other specialties. Good Samaritan Hospital - Cincinnati is involved with conducting 326 clinical trials across 539 conditions. There are 7 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Patrick Muck, MD, and Saulius Girnius.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
174 reported clinical trials
240 drugs studied
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
111 reported clinical trials
176 drugs studied
Patrick Muck, MDTriHealth-Hatton Research Institute3 years of reported clinical research
Studies Deep Vein Thrombosis
Studies Carotid Artery Disease
7 reported clinical trials
7 drugs studied
Saulius GirniusTriHealth Cancer Institute - Medical Oncology and Hematology Westside2 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
3 reported clinical trials
9 drugs studied
Clinical Trials running at Good Samaritan Hospital - Cincinnati
Breast Cancer
Cancer
Lung Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Gastric Cancer
Multiple Myeloma
Pancreatic Cancer
Tumors
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Good Samaritan Hospital - Cincinnati?
Good Samaritan Hospital - Cincinnati is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Lung Cancer, Recurrence and other specialties. Good Samaritan Hospital - Cincinnati is involved with conducting 326 clinical trials across 539 conditions. There are 7 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Patrick Muck, MD, and Saulius Girnius.
Where is Good Samaritan Hospital - Cincinnati located?
**Good Samaritan Hospital - Cincinnati, Ohio**
- **Address:** 375 Dixmyth Ave, Cincinnati, Ohio
- **Parking Information:**
- Non-emergency patients and visitors: Garage accessible from Dixmyth Avenue.
- Emergency department and breast center visitors: Garage accessible from Clifton Avenue.
Who should I call to ask about financial aid or insurance network?
**Good Samaritan Hospital Financial Assistance Contact Information:**
- **Mail:** Financial Assistance, TriHealth, Inc., PO Box 639461, Cincinnati, Ohio 45263-9461
- **Email:** THHCAPFinAsst@TriHealth.com
- **Fax:** (513) 853-4742
**Insurance Inquiries:**
- **Phone:** (866) 904-6871
What insurance does Good Samaritan Hospital - Cincinnati accept?
Good Samaritan Hospital - Cincinnati, part of TriHealth, accepts most major insurance plans. It is recommended to confirm your plan's coverage with your insurance provider.
What awards or recognition has Good Samaritan Hospital - Cincinnati received?
Good Samaritan Hospital, located in Cincinnati, Ohio, is celebrated for its exceptional healthcare services. It has been ranked as the fourth-best hospital in the Cincinnati area by U.S. News & World Report for 2023-24. Furthermore, it boasts the Comprehensive Stroke Center designation from The Joint Commission, distinguishing it within the top 3.5% of U.S. hospitals for stroke care.